how to track glp-1 injections Why GLP‑1 users need a new kind of health tracking app GLP-1 Medication Tracker: Weight Loss,
Description
A.SchauerP
Adverse events, primarily gastrointestinal, were mostly mild to moderate and related to dosage, with lower starting doses helping mitigate them
GIP receptor agonism attenuates GLP-1 receptor agonist induced nausea and emesis in preclinical models
Supports digestive and immune health
Although patients at risk for diabetes (ie, prediabetes, defined as a hemoglobin A1C 5.7% to 6.4% or a fasting blood glucose level 100 to 125 mg/dL) were included in FDA registration trials of Saxenda or Wegovy, prediabetes is not an FDA indication for any GLP-1 agonist
